Table 2.
Changes in clinical and vascular parameters after 12 months.
| Placebo (n = 29) | D&G (1 gm/day) (n = 31) | D&G (2 gm/day) (n = 30) | ||||
|---|---|---|---|---|---|---|
| Baseline | 12 months | Baseline | 12 months | Baseline | 12 months | |
| SBP (mmHg) | 124.4 ± 17.8 | 136.0 ± 24.0 | 132.3 ± 13.5 | 127.3 ± 11.0 | 134.9 ± 18.8 | 140.3 ± 14.6 |
| DBP (mmHg) | 78.7 ± 13.7 | 81.90 ± 12.50 | 88.0 ± 7.6 | 84.1 ± 8.3 | 82.9 ± 11.0 | 84.4 ± 7.1 |
| TC (mmol/L) | 4.8 ± 0.9 | 4.7 ± 1.0 | 5.4 ± 1.1 | 5.1 ± 1.0 | 5.2 ± 0.9 | 5.0 ± 0.9 |
| TG (mmol/L) | 2.0 ± 1.4 | 2.0 ± 1.5 | 2.2 ± 1.7 | 1.8 ± 1.3 | 1.7 ± 0.8 | 1.6 ± 0.9 |
| HBA1C (%) | 7.5 ± 2.6 | 7.3 ± 2.1 | 6.8 ± 2.0 | 7.0 ± 2.4 | 6.4 ± 1.0 | 6.6 ± 0.9 |
| Creatinine (mol/L) | 110.0 ± 40.6 | 109.4 ± 50.3 | 127.9 ± 58.0 | 130.0 ± 64.0 | 110.1 ± 49.3 | 110.4 ± 83.2 |
| Reactive hyperemia (%) | 543 ± 192 | 485 ± 105 | 615 ± 208 | 606 ± 154 | 535 ± 206 | 505 ± 133 |
| FMD (%) | 5.5 ± 1.3 | 6.2 ± 1.1* | 5.4 ± 1.9 | 7.0 ± 2.1** | 5.0 ± 1.5 | 6.2 ± 1.6** |
| NTG (%) | 15.2 ± 2.5 | 15.9 ± 3.0 | 18.3 ± 11.9 | 16.7 ± 3.3 | 15.4 ± 3.3 | 16.1 ± 3.1 |
| IMT (mm) | 0.80 ± 0.18 | 0.81 ± 0.17 | 0.79 ± 0.20 | 0.74 ± 0.16** | 0.85 ± 0.16 | 0.82 ± 0.15** |
Compared with baseline within group: *P = 0.001; **P < 0.0001. SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total cholesterol, TG: triglyceride, HBA1-C: hemoglobin A1-C, FMD: flow-mediated dilation, NTG: nitroglycerin-induced dilation, and IMT: intima-media thickness, Reactive hyperemia = (velocity − time integral2 × heart rate2)/(velocity − time integral1 × heart rate1) × 100.